Real-world treatment patterns and clinical outcomes in patients receiving palbociclib for hormone receptor–positive, human epidermal growth factor receptor 2 …

J Waller, D Mitra, K Mycock, G Taylor-Stokes… - Journal of Global …, 2019 - ascopubs.org
PURPOSE The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in
Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human …

Burden of illness in not adequately controlled chronic hypoparathyroidism: findings from a 13‐country patient and caregiver survey

…, N Bent‐Ennakhil, D Judge, K Mycock… - Clinical …, 2020 - Wiley Online Library
Objective To address knowledge gaps regarding burdens associated with not adequately
controlled chronic hypoparathyroidism. Design Global patient and caregiver survey. Study …

[HTML][HTML] Real-world palbociclib use in HR+/HER2− advanced breast cancer in Canada: the IRIS study

K Mycock, L Zhan, G Taylor-Stokes, G Milligan… - Current Oncology, 2021 - mdpi.com
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in
combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-…

Forest schools: moving towards an alternative pedagogical response to the Anthropocene?

K Mycock - Discourse: Studies in the Cultural Politics of Education, 2020 - Taylor & Francis
In this paper I consider whether forest schools provide a space where we could rethink
pedagogy in the Anthropocene. I explore the challenges and possibilities of thinking beyond the …

Playing with mud-becoming stuck, becoming free?… The negotiation of gendered/class identities when learning outdoors

K Mycock - Children's Geographies, 2019 - Taylor & Francis
In recent years there has been a growth in outdoor learning opportunities for children of
primary school age in part due to concerns that children spend less time outdoors and have …

Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study

K Mycock, L Zhan, K Hart, G Taylor-Stokes… - Future …, 2021 - Future Medicine
Aim: To report the Europe Ibrance Real World Insights study findings. Methods: Physicians
abstracted demographic/clinical characteristics, treatment and outcomes data for women with …

[HTML][HTML] Real-world treatment patterns and clinical outcomes associated with palbociclib combination therapy: a multinational, pooled analysis from the Ibrance real …

K Mycock, KA Hanson, G Taylor-Stokes, G Milligan… - Clinical Therapeutics, 2022 - Elsevier
Purpose Palbociclib was the first cyclin-dependent kinase 4/6 inhibitor approved by the US
Food and Drug Administration for use in combination with aromatase inhibitors (AIs) as initial …

People living with moderate-to-severe COPD prefer improvement of daily symptoms over the improvement of exacerbations: a multicountry patient preference study

NS Cook, GJ Criner, PR Burgel, K Mycock… - ERJ Open …, 2022 - Eur Respiratory Soc
Introduction This patient preference study sought to quantify the preferences of people living
with COPD regarding symptom improvement in the UK, USA, France, Australia and Japan. …

[HTML][HTML] Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2–advanced/metastatic breast cancer in …

K Mycock, L Zhan, K Hart, G Taylor-Stokes… - Cancer Treatment and …, 2022 - Elsevier
Background The incidence of breast cancer is rising in Japan, particularly in postmenopausal
women. The CDK 4/6 inhibitor palbociclib has demonstrated efficacy in clinical studies in …

[HTML][HTML] Real-world experience with dolutegravir-based two-drug regimens

…, S Dhir, J Waller, J Roberts, K Mycock… - AIDS Research and …, 2020 - hindawi.com
Background. Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as
alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on …